The nation of Zimbabwe has declined a major US health deal valued at $367m (£272m) spanning five years due to the United States' demand for confidential biological samples.
This move came to light after a official document dated December was disclosed, indicating that President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesperson has since stated that the US was seeking genetic material for research and commercial purposes but was unwilling to share the resulting advantages from future medical innovations.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for more dialogue to secure a deal agreeable to both sides so the country's critical HIV treatment initiative can proceed.
Wider Implications
This rejection follows a similar case in neighbouring Kenya, where a court suspended a related health funding agreement after legal challenges were raised about the safety of Kenyans' health data.
Since returning to office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its spending was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
According to reports, 16 African countries have to date agreed to similar agreements, constituting more than $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation could have provided significant advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to surrender its biological resources and data over an extended period, with no corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that might result from that shared data," he stated.
"Effectively, our nation would supply the raw materials for scientific discovery without any assurance that the resulting innovations would be available to our citizens if a new pandemic emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were disrupting structures already established via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to manage future global health emergencies.
"This framework is intended to guarantee that when a nation provides its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We are open to further dialogue with our American counterparts on how future collaboration could be designed in a way that honours the independence and dignity of both nations."
Medical Community Reaction
A leading public health body stated it recognised the government's concerns, but suggested that talks should continue given that a large portion of the country's HIV programmes were funded by external financing.
"Where technical issues arise, such as those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
This impasse emphasises the continuing debate between receiving vital foreign assistance and protecting a country's data in an ever more interconnected world.